Decoding The Epitranscriptome: In Silico Insights Into m6A Regulatory Network In Breast Cancer

N6-methyladenosine (m6A) is the most abundant internal RNA modification in eukaryotic transcripts and plays a critical role in RNA metabolism, gene expression, and cellular homeostasis. Dysregulation of m6A regulators, including “writers,” “erasers,” and “readers”, has been increasingly implicated in cancer biology; however, their comprehensive roles in breast cancer remain to be understood. The primary objective of this methods article is to provide bioinformatics beginners with a step-by-step framework for utilizing publicly available cancer datasets to perform mutational analyses, assess gene expression alterations, and examine their associations with patient survival. As a case study, m6A regulators in breast cancer were analyzed using datasets from the Cancer Genome Atlas (TCGA), the Genotype-Tissue Expression (GTEx) project, and microarray platforms. Transcriptomic profiles were systematically analyzed to demonstrate workflows for evaluating the prognostic relevance of m6A regulatory components in breast cancer. Using this analytical framework, distinct patterns of genetic alterations and differential expression among key m6A regulators were identified. Several regulators, including METTL14, CBLL1, YTHDC1, HNRNPC, HNRNPA2B1, and RBMX, were associated with better patient survival, while YWHAG was associated with poor overall survival. This study provides a comprehensive systems genomics overview of m6A regulatory genes in breast cancer while demonstrating a practical and reproducible web-based bioinformatics workflow. These findings advance the understanding of epitranscriptomic regulation in breast cancer and offer a foundation for the development of novel m6A-based diagnostic and therapeutic strategies.